Inventiva Stock Plunges 11.5% After Piper Sandler Initiates Coverage

Inventiva's stock experienced a significant drop of 11.5% in pre-market trading on August 29, 2025, marking a notable decline in its share price.

Piper Sandler initiated coverage on Inventiva with an Overweight rating and a price target of $26. This move by Piper Sandler has been a significant factor in the recent volatility of Inventiva's stock. The firm's positive outlook on Inventiva's lead asset, lanifibranor, has contributed to the stock's recent performance.

Inventiva's stock has seen a notable increase of 15% following Piper Sandler's initiation of coverage with an Overweight rating. This rating reflects the firm's confidence in Inventiva's flagship drug, lanifibranor, and its potential in the market.

Piper Sandler's initiation of coverage on Inventiva with an Overweight rating has been a significant development for the company. This move by the firm has been closely watched by investors, as it marks a positive outlook on Inventiva's prospects in the biopharmaceutical sector.